Compare INSM & CCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | CCL |
|---|---|---|
| Founded | 1988 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 34.2B |
| IPO Year | 2000 | 1987 |
| Metric | INSM | CCL |
|---|---|---|
| Price | $165.46 | $28.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 17 |
| Target Price | ★ $188.05 | $34.94 |
| AVG Volume (30 Days) | 3.1M | ★ 19.9M |
| Earning Date | 10-30-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.65 |
| EPS | N/A | ★ 1.94 |
| Revenue | $447,022,000.00 | ★ $26,230,000,000.00 |
| Revenue This Year | $43.10 | $7.63 |
| Revenue Next Year | $128.25 | $4.33 |
| P/E Ratio | ★ N/A | $14.46 |
| Revenue Growth | ★ 30.34 | 7.15 |
| 52 Week Low | $60.40 | $15.07 |
| 52 Week High | $212.75 | $32.80 |
| Indicator | INSM | CCL |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 60.01 |
| Support Level | $192.50 | $25.27 |
| Resistance Level | $205.23 | $29.04 |
| Average True Range (ATR) | 7.18 | 0.75 |
| MACD | -3.77 | 0.37 |
| Stochastic Oscillator | 6.57 | 79.97 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.